Table 5 Variables associated with 28-day mortality
|  | All n = 151 | Alive n = 97 | Dead n = 54 | p value |
|---|---|---|---|---|
Age, year | 58 ± 14 | 57 ± 15 | 59 ± 13 | 0.40 |
Female gender, n (%) | 58 (38) | 41 (43) | 17 (32) | 0.71 |
SAPS2 | 52 ± 17 | 47 ± 13 | 62 ± 19 | < 0.01 |
SOFA | 9 ± 4 | 7 ± 3.5 | 11 ± 4.5 | < 0.01 |
TIVAP-related infection | 68 (45) | 55 (57) | 13 (24) | < 0.05 |
TIVAP-related infection risk factors, n (%) | ||||
 Immunosuppression | 148 (98) | 97 (100) | 51 (95) | 0.99 |
 Hematological malignancies | 72 (48) | 43 (44) | 29 (54) | < 0.05 |
 Solid organ cancer | 71 (47) | 52 (54) | 19 (35) | 0.12 |
 Metastatic cancer | 44 (29) | 31 (32) | 13 (24) | 0.55 |
 Recent chemotherapy (< 6 months) | 131 (87) | 88 (91) | 43 (80) | 0.85 |
 Parenteral nutrition | 18 (12) | 13 (14) | 5 (9) | 0.34 |
Initial presentation | ||||
 Systolic blood pressure, mmHg | 98 ± 27 | 98 ± 27 | 101 ± 28 | 0.55 |
 Mean blood pressure, mmHg | 69 ± 20 | 69 ± 19 | 72 ± 24 | 0.44 |
 Glasgow Score Scale | 13 ± 3 | 14 ± 3 | 13 ± 3 | 0.20 |
 White blood cells, Giga/l | 7.6 ± 13.2 | 7.6 ± 15.6 | 7.6 ± 10.2 | 0.98 |
 Platelet counts, Giga/l | 116 ± 113 | 128 ± 110 | 91 ± 114 | < 0.05 |
 Prothrombin time, % | 64 ± 17 | 68 ± 15 | 55 ± 19 | < 0.01 |
 Serum creatinine, μmol/l | 142 ± 119 | 125 ± 106 | 176 ± 137 | 0.01 |
 Bicarbonate, mmol/l | 20 ± 5 | 21 ± 6 | 19 ± 5 | < 0.01 |
 Arterial blood lactate, mmol/l | 3.4 ± 3.2 | 2.7 ± 2.2 | 5 ± 4 | < 0.01 |
Treatments | ||||
 Time between ICU admission and device withdrawal, days | 1.8 ± 3.5 | 1.6 ± 2.8 | 2.2 ± 4.5 | 0.35 |
 Use of MV, n (%) | 74 (49) | 37 (38) | 37 (69) | < 0.01 |
 MV duration, days | 4 ± 7 | 4 ± 7 | 5 ± 5 | 0.32 |
 Use of vasopressors, n (%) | 103 (68) | 62 (64) | 41 (76) | < 0.01 |
 Vasopressors duration, days | 3 ± 4 | 2 ± 3 | 4 ± 5 | < 0.01 |
 ICU stay, days | 8 ± 9 | 9 ± 10 | 8 ± 7 | 0.53 |